Enzo Biochem, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 24   

Articles published

ENZ 4.80 -0.09 (-1.84%)
price chart
What Falling Estimates & Price Mean for Enzo Biochem (ENZ) - Tale of the Tape
One such stock that you may want to consider dropping is Enzo Biochem Inc. ( ENZ ), which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Related articles »  
Watch List: SandRidge Energy (NYSE:SD), Intel Corporation (NASDAQ:INTC ...
On 7 October Enzo Biochem Inc. (NYSE:ENZ) announced that the U.S. Patent and Trademark Office has awarded the Company Patent for novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.
Enzo Biochem Inc. (ENZ) Drops 5.7% on September 23
Enzo Biochem Inc. (ENZ) was one of the Russell 2000's biggest losers for September 23 as the stock slid 5.7% to $4.96, a loss of $0.30 per share.
Related articles »  
Enzo Biochem Inc. (ENZ) Drops 5.67% on September 19
Enzo Biochem Inc. (ENZ) was one of the Russell 2000's biggest losers for September 19 as the stock slid 5.67% to $5.32, a loss of $0.32 per share.
Related articles »  
Enzo Biochem Awarded Patent for Novel Vectors Involving Gene Therapy ...
NEW YORK, Oct 07, 2014 (BUSINESS WIRE) -- Enzo Biochem, Inc. ENZ, -1.99% today announced that the U.S. Patent and Trademark Office has awarded the Company Patent No.
Enzo Biochem Granted Patent For Novel Vectors - Quick Facts  RTT News
Related articles »  
Enzo Biochem Schedules Teleconference to Discuss Fourth Quarter Results ...
NEW YORK, Oct 06, 2014 (BUSINESS WIRE) -- Enzo Biochem, Inc. ENZ, -0.61% will hold a conference call to discuss fiscal 2014 fourth quarter results, Friday, October 10, 2014, at 8:30 AM E.T.. To listen to the conference call dial 1-888-459-5609.
Related articles »  
Enzo Biochem Reports Strong Fiscal Fourth Quarter Results
NEW YORK, Oct 09, 2014 (BUSINESS WIRE) -- Enzo Biochem Inc. ENZ, +0.62% today reported results for the fourth quarter and fiscal year ended July 31, 2014, with continued solid year-end gains posted by both Life Sciences and Clinical Labs.
Related articles »  
Enzo Pays $3.5M To End FCA Medicare Billing Suit
Law360, New York (September 25, 2014, 1:24 PM ET) -- Enzo Biochem Inc. has agreed to pay $3.5 million to settle state and federal False Claims Act allegations that the life sciences company sought to unlawfully increase Medicare and Medicaid profits by ...
Related articles »  
Stockwatch: Globalstar, Inc. (NYSEMKT:GSAT), KCAP Financial Inc (NASDAQ ...
Enzo Biochem, Inc. (NYSE:ENZ) said Tuesday it was awarded a patent by the USPTO, which covers novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.
Related articles »  
Hot News: Cisco Systems, Inc. (NASDAQ:CSCO), Citigroup Inc. (NYSE:C ...
... Inc. and Rocky Holding, Inc. TriQuint Semiconductor, Inc. (NASDAQ:TQNT) has 0.30% insider ownership while its institutional ownership stands at 88.40%.